George S. Golumbeski, Ph.D. Dr. Golumbeski has served as a member of its Board of Directors since January 2019. Since October 2020, Dr. Golumbeski has served as a partner at DROIA Ventures, a venture capital firm focused on therapeutics for oncology and genetic disease, and previously served as the President of GRAIL, Inc., a health-care company focused on the early detection of cancer, from August 2018 to September 2019. From 2009 to April 2018, Dr. Golumbeski was employed by Celgene Corporation, or Celgene, as Executive Vice President of Business Development.

Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Earlier in his career, he held leadership positions at Elan Pharmaceuticals Inc. and Schwarz Pharma AG, where he focused on neurology and neuropsychiatry therapeutics. Dr. Golumbeski has served on the boards of directors of Shattuck Labs, Inc., a public clinical-stage biotechnology company focused on cancer and autoimmune disease, since January 2018 and MorphoSys AG, a public commercial-stage biopharmaceutical company focused on cancer, since May 2018.

He previously served on the board of directors of Enanta Pharmaceuticals, Inc., a public clinical stage biotechnology company focused on viral infections from February 2014 through March 2021. He also serves on the boards of directors of various private companies. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in Genetics from the University of Wisconsin?Madison.

The company believe Dr. Golumbeski?s qualifications to sit on its Board of Directors include his years of experience in research and development, business development and leadership at various pharmaceutical companies. Barry E. Greene. Mr. Greene has served as its Chief Executive Officer and President since December 2020 and as a member of its Board of Directors since October 2020.

Mr. Greene served as President of Alnylam Pharmaceuticals, Inc., or Alnylam, a public biopharmaceutical company, from 2007 through September 2020, and served as its Chief Operating Officer from 2003 to September 2016. Prior to Alnylam, he was General Manager of Oncology at Millennium Pharmaceuticals, Inc., a public biopharmaceutical company. Prior to joining Millennium in 2001, Mr. Greene served as Executive Vice President and Chief Business Officer for Mediconsult.com, a healthcare consulting company.

Prior to joining Mediconsult.com, Mr. Greene?s experience included serving as Vice President of Marketing and Customer Services for AstraZeneca (formerly AstraMerck), a pharmaceutical company; Vice President, Strategic Integration with responsibility for the AstraZeneca North American post-merger integration; and a partner of Andersen Consulting, a consulting company. Mr. Greene has served as a member of the board of directors of Karyopharm Therapeutics, Inc., since 2013 and previously served as a member of the boards of directors of Acorda Therapeutics, Inc., a public biotechnology company focused on nervous system disorders, from January 2007 to August 2021 and BCLS Acquisition Corporation, a former special purpose acquisition company, from October 2020 to October 2022. Mr. Greene received his B.S. in Industrial Engineering from the University of Pittsburgh and served as a Senior Scholar at Duke University?s Fuqua School of Business.

The company believe Mr. Greene?s qualifications to sit on its Board of Directors include his extensive experience and leadership in the healthcare and biopharmaceutical industries, including his experience serving as Chief Executive Officer at Sage. Jeffrey M. Jonas, M.D. Dr. Jonas has served as a member of its Board of Directors since August 2013. Dr. Jonas is a partner at Cure Ventures, a life sciences venture capital firm.

Prior to joining Cure Ventures in 2024, Dr. Jonas served as Chief Executive Officer and a Director of ABio-X, a private biotechnology incubator from November 2022 to January 2024. From December 2020 to November 2022, Dr. Jones served as its Chief Innovation Officer. Prior to assuming his role as Chief Innovation Officer, he had served as its President and Chief Executive Officer from August 2013 to December 2020.

From 2012 to 2013, Dr. Jonas served as the President of the Regenerative Medicine Division of Shire, and from 2008 to 2012 as Senior Vice President of Research and Development, Pharmaceuticals at Shire. Dr. Jonas served from 2007 to 2008 as the Executive Vice President of Ionis Pharmaceuticals, Inc., formerly known as ISIS Pharmaceuticals, Inc.; from 2006 to 2007 as Chief Medical Officer and Executive Vice President of Forest Laboratories, Inc.; and from 1991 to 1996 in senior-level positions at Upjohn Laboratories. Dr. Jonas also founded AVAX Technologies, Inc. and SCEPTOR Industries, Inc., where he served as the Chief Executive Officer, President and a Director.

Dr. Jonas currently serves on the board of directors of Generation Bio Co., a public biotechnology company, and Noema Pharma AG, a private biotechnology company. Dr. Jonas also served on the board of directors of Karuna Therapeutics, Inc., or Karuna, a public biopharmaceutical company, from October 2018 until its acquisition by Bristol Myers Squibb in March 2024. Dr. Jonas has authored more than 200 books, provided guidance on scientific articles and abstracts, and has received numerous awards.

Dr. Jonas received his B.A. from Amherst College and M.D. from Harvard Medical School. He completed a residency in psychiatry at Harvard Medical School, and he served as Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School. The company believe Dr. Jonas?

qualifications to serve on its Board of Directors include his over 20 years of experience on both the scientific and business sides of the pharmaceutical and healthcare industries, particularly in the central nervous system field, including his past experience serving as Chief Executive Officer and Chief Innovation Officer at Sage.